ProQR Therapeutics (NASDAQ:PRQR) Releases Earnings Results, Hits Estimates

ProQR Therapeutics (NASDAQ:PRQR) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10), Zacks reports. ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%.

ProQR Therapeutics Stock Down 5.9 %

Shares of PRQR stock opened at $1.74 on Friday. The firm has a 50 day moving average price of $2.27 and a two-hundred day moving average price of $2.62. The company has a market capitalization of $142.12 million, a PE ratio of -5.44 and a beta of 0.24. ProQR Therapeutics has a 12-month low of $1.61 and a 12-month high of $4.62.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PRQR. StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Oppenheimer began coverage on shares of ProQR Therapeutics in a research note on Friday, January 10th. They issued an “outperform” rating and a $15.00 target price for the company. Citigroup upgraded shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 target price for the company in a research note on Monday. JMP Securities reiterated a “market outperform” rating and issued a $8.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Finally, Chardan Capital reiterated a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $9.17.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).